

IN THE SPECIFICATION:

The following changes have been made:

The first paragraph of the Specification has been amended as follows:

TECHNICAL FIELD

C³ The present invention relates to a mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) which polypeptide is useful for the inhibition of angiogenesis and/or tumor progression. The invention also relates to screening methods for compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

The paragraph bridging pages 6 and 7 has been amended as follows:

C³ Consequently, in a first aspect this invention provides an isolated nucleic acid molecule selected from:

(a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 2;

(b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary to the polypeptide coding region of a nucleic acid molecule as defined in (a) and which codes for a biologically active mammalian IPAS polypeptide or a functionally equivalent modified form thereof; and

(c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for a biologically active mammalian IPAS polypeptide or a functionally equivalent modified form thereof.

The paragraph bridging pages 7 and 8 has been amended as follows:

C⁴ In a preferred form of the invention, the ~~said~~ nucleic acid molecule has a nucleotide sequence identical to ~~with~~ SEQ ID NO: 2 of the Sequence Listing. However, the nucleic acid molecule according to the invention is not to be limited ~~strictly~~ to the sequence shown as

